September 19, 2014 8:32 PM ET

Pharmaceuticals

Company Overview of Novo Nordisk, Inc.

Company Overview

Novo Nordisk, Inc. operates a healthcare company focusing on diabetes care. The company manufactures a line of human insulin and insulin analog products for individuals with diabetes. It also offers products and services for therapeutic areas, such as bleeding episodes in people with hemophilia who have inhibitors; human growth hormone and advanced delivery systems that include cartridges for children with short stature due to growth hormone deficiency; and hormone therapy products for women. In addition, the company operates a research center for biopharmaceutical research projects; and to build the clinical pipeline of products for the treatment of chronic inflammatory diseases. It offers ...

100 College Road West

Princeton, NJ 08540

United States

Founded in 1982

Phone:

609-987-5800

Fax:

609-919-7713

Key Executives for Novo Nordisk, Inc.

President
Senior Vice President of Commercial Effectiveness
Age: 47
Chief Executive Officer of Novo Nordisk A/S and President of Novo Nordisk A/S
Age: 60
Corporate Vice President and General Counsel
Chief Compliance Officer and Vice President of Compliance
Compensation as of Fiscal Year 2014.

Novo Nordisk, Inc. Key Developments

Novo Nordisk Promotes Eddie Williams to Senior Vice President of Biopharmaceuticals, Effective February 1, 2014

Novo Nordisk announced the promotion of Eddie Williams to senior vice president of biopharmaceuticals, effective February 1, 2014. Eddie brings three decades of experience in the pharmaceutical industry. He joined Novo Nordisk in 2006 and currently serves as the corporate vice president of biopharmaceuticals. In this capacity, he leads the sales and marketing, business development and new product commercialization functions for the company's growing U.S. biopharmaceuticals business, which develops medicines for people with hemophilia, as well as various types of hormone deficiencies.

Novo Nordisk, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2013; Provides Earnings Guidance for the Year 2013 and 2014

Novo Nordisk, Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2013. For the quarter, the company reported sales of DKK 20,511 million compared to DKK 19,845 million a year ago. Operating profit was DKK 7,992 million compared to DKK 7,864 million a year ago. Profit before income taxes was DKK 8,299 million compared to DKK 7,359 million a year ago. Net profit was DKK 6,415 million compared to DKK 5,667 million a year ago. Capital expenditure was DKK 908 million compared to DKK 942 million a year ago. Net cash generated from operating activities were DKK 6,217 million compared to DKK 7,962 million a year ago. Free cash flow was DKK 5,219 million compared to DKK 6,926 million a year ago. Diluted earnings per share/ADR were DKK 11.96 compared to DKK 10.33 a year ago. For the nine months, the company reported sales of DKK 61,874 million compared to DKK 57,064 million a year ago. Operating profit was DKK 24,139 million compared to DKK 21,902 million a year ago. Profit before income taxes was DKK 24,749 million compared to DKK 20,359 million a year ago. Net profit was DKK 19,131 million compared to DKK 15,677 million a year ago. Diluted earnings per share/ADR were DKK 35.39 compared to DKK 28.32 a year ago. Net cash generated from operating activities were DKK 20,570 million compared to DKK 20,700 million a year ago. Purchase of property, plant and equipment was DKK 2,478 million compared to DKK 2,330 million a year ago. For 2013, expectations to operating performance in local currencies are unchanged. Sales growth measured in local currencies is expected to be 11%-13% and operating profit growth measured in local currencies is expected to be 12%-15%. The preliminary outlook for 2014 indicates high single-digit growth in sales and operating profit, both measured in local currencies.

Novo Nordisk, Inc. to Report Fiscal Year 2013 Results on Jan 30, 2014

Novo Nordisk, Inc. announced that they will report fiscal year 2013 results on Jan 30, 2014

Similar Private Companies By Industry

Company Name Region
Metabolic Nutrition, Inc. United States
Proventiv Therapeutics, L.L.C. United States
Stiefel Laboratories, Inc. United States
Essential Resources, Inc. United States
Organic Science, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Novo Nordisk, Inc., please visit www.novonordisk-us.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.